CA1 and acute myeloid leukemia: The autoantibody response in AML patients has been considered in previous studies, such as Wilms tumor gene product [28], single-stranded DNA [29], anti-cardiolipin antibodies [30], the M-phase phosphoprotein 11 (MPP11) [31], receptor for hyaluronan acid-mediated motility (RHAMM) [32], and RHAMM-like protein [33]. This study is the first report to show an increased autoimmune response to both CA I and II in the sera of AML patients.